Atosiban

This classification denotes a hormone antagonist with the molecular formula C43H67N11O12S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 081D12SI0Z, chemically known as oxytocin, 1-(3-mercaptopropanoic acid)-2-(o-ethyl-d-tyrosine)-4-l-threonine-8-l-ornithine- but generally known as atosiban, which bears US NIH Compound Identifier 68613. European Medicines Agency schedules Atosiban in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05601MIG. The term ATOSIBAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). World Health Organization schedules atosiban in its Anatomical Therapeutic Chemical (ATC) Classification. ATOSIBAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule atosiban under HS 29349990 and SITC 51579. As of Q4 2014, ATOSIBAN remains the US FDA Preferred Term for this commodity. Atosiban bears US NLM identifiers UMLS ID C0164398 and NCI Concept Code C84815. SMILES: S1SCCC(=O)NC(C(=O)NC(C(CC)C)C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2C(CCC2)C(=O)NC(CCCN)C(=O)NCC(=O)N)C1)CC(=O)N)C(O)C)CC1CCC(OCC)CC1.